SARS-CoV-2 Infection and Risk of Demyelinating Diseases
Author Information
Author(s): Scott Montgomery, Snieguole Vingeliene, Huiqi Li, Helena Backman, Ruzan Udumyan, Johan Jendeberg, Gunlög Rasmussen, Martin Sundqvist, Katja Fall, Ayako Hiyoshi, Fredrik Nyberg
Primary Institution: Örebro University
Hypothesis
Is SARS-CoV-2 infection associated with subsequent diagnoses of demyelinating diseases?
Conclusion
Hospital admission for COVID-19 is linked to an increased risk of both non-multiple sclerosis demyelinating diseases and multiple sclerosis.
Supporting Evidence
- Hospital admission for COVID-19 was associated with a raised risk of subsequent non-multiple sclerosis demyelinating disease.
- Only a small number of non-multiple sclerosis demyelinating disease diagnoses were associated with hospital admission for COVID-19.
- 28 individuals were diagnosed with multiple sclerosis following hospital admission for COVID-19.
Takeaway
Getting really sick from COVID-19 might make you more likely to get certain brain diseases later on.
Methodology
The study followed all residents of Sweden aged 3–100 years from January 2020 to November 2022, excluding those with prior demyelinating diseases, and used Cox regression to assess risks.
Potential Biases
There may be shared susceptibility or surveillance bias affecting the results.
Limitations
The study's outcomes were based on hospital admissions, which may not capture all cases, and the small number of diagnoses raises questions about diagnostic accuracy.
Participant Demographics
The study included individuals aged 3 to 100 years, with a mix of genders and varying health statuses.
Statistical Information
P-Value
0.004 for non-multiple sclerosis demyelinating diseases; <0.001 for multiple sclerosis
Confidence Interval
2.35 (1.32–4.18) for non-multiple sclerosis; 2.48 (1.70–3.61) for multiple sclerosis
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website